Ads
related to: pembrolizumab maintenance therapy for prostate cancer- Real People, Real Stories
Visit Site to Watch Patient Videos
& Learn About Their Journey.
- Clinical Study Results
View Clinical Study Results
and Study Data Information.
- Starting Treatment
Learn How to Find a Specialty
Pharmacy to Obtain Treatment.
- Sign Up for Support
Sign Up to Receive Educational
Materials About Treatment.
- Real People, Real Stories
Search results
Results from the WOW.Com Content Network
Pembrolizumab (Pembro) use for treatment of Lung cancer in the first line with or without chemotherapy (Chemo). Median overall survival in months (M). Hazard Ratio (HR). [27] Keytruda (pembrolizumab [28]) is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of various types of cancer, including: Melanoma [29]:
Treatment of adults with relapsed or refractory multiple myeloma, who previously received a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody [3] Dupixent: As an add-on maintenance treatment in adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype [2 ...
Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early-stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer.
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9]
Therapies with specific molecular or genetic targets, which inhibit growth-promoting signals from classic endocrine hormones (primarily estrogens for breast cancer and androgens for prostate cancer), are now called hormonal therapies. Other inhibitions of growth-signals, such as those associated with receptor tyrosine kinases, are targeted therapy.
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
Ads
related to: pembrolizumab maintenance therapy for prostate cancer